In this edition, Achalasia is associated with higher esophageal cancer risk; FDA rejects bulevirtide for hepatitis D and liver disease; real-world data on colonoscopy prep and more. Read the full coverage here: Achalasia associated with five-fold higher risk for esophageal cancer FDA rejects Gilead's bulevirtide for hepatitis D, compensated liver disease Polyethylene glycol, ascorbic acid cleanse highly effective for colonoscopy prep Distal cap-assisted endoscopic mucosal resection safe, effective for fibrotic polyps FDA backs EndoStim's neurostimulation implant for GERD control References: Arieira C, et al. Abstract S589: One-Liter Polyethylene Glycol + Ascorbic Acid Bowel Preparation Delivers High Levels of Adequate and High-Quality Bowel Cleansing for Colonoscopy. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). Douglas SR, et al. Abstract S130: Distal Cap-Assisted Endoscopic Mucosal Resection Is a Safe and Effective Technique for Resection of Non-Lifting or Adherent Colorectal Polyps: An International, Multicenter, Retrospective Study. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). Low EE, et al. Abstract S388: Risk of esophageal cancer in achalasia: A matched cohort study utilizing the veterans affairs achalasia cohort (VA-AC). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). Press Release Press Release

Ver todos los episodios